borderline significantp = 0.05
Significantly higher levels of ALCAM were observed in patients who died of prostate cancer (PRCa) compared to those who were still alive ( Figure 2A , p < 0.001) and in M1 patients compared to M0 patients ( Figure 2B , p = 0.002), with borderline significant elevations observed in N1 compared to N0 patients ( Figure 2C , p = 0.05).